CAPEGARD 500MG

About

Capecitabine is an oral fluoropyrimidine carbamate that is enzymatically converted to fluorouracil (5-FU) in the body, primarily within tumor cells. It is an antimetabolite chemotherapy agent used in the treatment of various cancers, including metastatic colorectal cancer, adjuvant colorectal cancer, and metastatic breast cancer. Capecitabine selectively targets cancer cells by exploiting their higher levels of thymidine phosphorylase, an enzyme that converts an intermediate metabolite into the active cytotoxic agent 5-FU.

This targeted activation leads to the inhibition of DNA and RNA synthesis, ultimately causing cell death in rapidly dividing cancer cells while minimizing systemic exposure to 5-FU. Its oral formulation offers convenience and improved quality of life for patients undergoing long-term cancer treatment, making it a cornerstone in several oncology regimens.

Uses

• Treatment of metastatic colorectal cancer.
• Adjuvant therapy for colon cancer.
• Treatment of metastatic breast cancer.
• Gastric cancer (in some regimens).

Directions For Use

Take orally with water within 30 minutes after a meal, twice daily, as prescribed by your oncologist. Do not crush or chew tablets.

Benefits

• Oral administration offers convenience.
• Targeted activation within tumor cells.
• Effective against various solid tumors.
• Can be used as monotherapy or in combination.
• Improved quality of life compared to IV 5-FU.
• Reduced need for hospital visits.

Side Effects

• Diarrhea
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Nausea
• Vomiting
• Stomatitis
• Fatigue
• Abdominal pain
• Anorexia
• Neutropenia
• Thrombocytopenia
• Hyperbilirubinemia
• Alopecia (less common)

Safety Measures

• Alcohol - Alcohol should be avoided during capecitabine treatment as it can exacerbate gastrointestinal side effects and liver toxicity.
• Pregnancy - Capecitabine is teratogenic and embryotoxic. It is contraindicated in pregnancy. Effective contraception must be used.
• Breastfeeding - Breastfeeding is contraindicated during capecitabine treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with mild to moderate liver impairment. Close monitoring of liver function is required.
• Kidney - Dosage adjustment is necessary for patients with moderate to severe renal impairment. Regular monitoring of kidney function is crucial.
• Lung - Rare cases of interstitial lung disease have been reported. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.